Welcome to the e-CCO Library!

DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ho-Su Lee
Created: Friday, 14 July 2023, 2:22 PM
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lee, H.S.(1)*;Lee, Y.(1);Baek, J.(1);Kim, Y.(1);Park, S.(1);Jung, S.(1);Kim, K.K.(2);Hwang, S.W.(2);Lee, J.L.(3);Park, S.H.(2);Yang, S.K.(2);Han, B.(4);Song, K.(1);Yoon, Y.S.(3);Ye, B.D.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. L. Hamilton*1, P. P. De Cruz1,2, E. K. Wright3, L. Okada4, M. Hale4, L. Mimms4, A. Jain4, M. A. Kamm1

Created: Friday, 22 February 2019, 9:41 AM
DOP81: Utility of a Simple Blood Test for Mucosal Healing Monitoring is Accurate in Post-Operative Crohn’s Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Amy L Hamilton
Created: Tuesday, 28 May 2019, 3:32 PM
Crohn’s disease, Colonoscopic surveillance, CRP and other serum biomarkers, Mucosal healing, Post operative medical management, Post-operative IBD, Mucosal healing
Files: 1
DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.M. Bloemendaal1, M. Becker1, P.J. Koelink1, J.D. van der Bilt2,3, W.A. Bemelman2, G.R.A.M. D’Haens4, C.J. Buskens2, M.E. Wildenberg1,4

Created: Thursday, 30 January 2020, 10:12 AM
DOP82: Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab
Year: 2022
Source: ECCO'22
Authors: Schreiber, S.W.(1);Cross, R.(2);Panaccione, R.(3);D'Haens, G.(4);Bossuyt, P.(5);Colombel, J.F.(6);Louis, E.(7);Dubinsky, M.(6);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Cheng, E.(8);Ferrante, M.(9);
Created: Friday, 11 February 2022, 3:52 PM
DOP82: Biological Treatment Cycles in Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Noor, N.(1)*;Sousa, P.(2);Bettenworth, D.(3);Gomollon, F.(4);Lobaton, T.(5,6);Bossuyt, P.(7);Casanova, M.J.(8);Ding, N.(9);Dragoni, G.(10,11);Furfaro, F.(12);van Rheenen, P.(13);Chaparro, M.(8);Gisbert, J.(8);Louis, E.(14);Papamichael, K.(15);
Created: Friday, 14 July 2023, 10:43 AM
DOP82: Biological Treatment Cycles in Crohn’s Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nurulamin Noor
Created: Friday, 14 July 2023, 2:22 PM
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
Year: 2021
Source: ECCO'21 Virtual
Authors: Loftus- Jr, E.(1);Vermeire, S.(2);Feagan, B.(3);Yun, C.(4);Hsieh, J.(4);Liu, X.(4);Zhao, S.(4);Moerch, U.(5);Sandborn, W.J.(6);Hibi, T.(7)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; 10 years of follow-up in a Danish population-based inception cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Lo*1, I. Vind1, M. K. Vester-Andersen1,2, F. Bendtsen1, J. Burisch1

Created: Friday, 22 February 2019, 9:41 AM
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; ten years of follow up in a Danish population-based inception cohort
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Bobby Lo
Created: Tuesday, 28 May 2019, 3:32 PM
Epidemiology, Natural history, Crohn’s disease, Ulcerative colitis, Health economic analysis
Files: 1
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectin
Year: 2020
Source: ECCO'20 Vienna
Authors: Marte Becker
Created: Tuesday, 23 June 2020, 5:40 PM
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectin
Year: 2020
Source: ECCO'20 Vienna
Authors: Marte Becker
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Creyns1,2, D. Gabriele3, C. Jonathan1,2, B. Verstockt2, G. Bislenghi4, F. Marc2,4, S. Vermeire2,4, G. Van Assche2,4, J. Ceuppens1, A. D’Hoore4, G. De Hertogh5, C. Breynaert1,6, Allergy and Clinical Immunology Research Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP83: Association of FUT2 and ABO with Crohn’s disease in Koreans
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H-S. Lee*1,2, B. M. Kim2, S. Jung2, M. Hong2, K. Kim2, J. W. Moon2, J. Baek2, S. W. Hwang3, S. H. Park3, S-K. Yang3, K. Song2, B. D. Ye3

Created: Friday, 22 February 2019, 9:41 AM
DOP83: Association of FUT2 and ABO with Crohn’s disease in Koreans
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Ho-Su Lee
Created: Tuesday, 28 May 2019, 3:32 PM
Genetic factors, Genetics
Files: 1
DOP83: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
Year: 2021
Source: ECCO'21 Virtual
Authors: Abreu, M.T.(1);Danese, S.(2);Sandborn, W.J.(3);Miao, Y.(4);Tikhonov, I.(4);Zhang, H.(4);Panaccione, R.(5);Hisamatsu, T.(6);Scherl, E.J.(7);Leong, R.W.(8);Rowbotham, D.S.(9);Arasaradnam, R.P.(10);Afif, W.(11);Peyrin-Biroulet, L.(12);Sands, B.E.(13);Marano, C.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP83: Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Year: 2022
Source: ECCO'22
Authors: Atreya, R.(1);Feagan, B.(2);Shchukina, O.(3);Jairath, V.(4);Rieder, F.(5);Hisamatsu, T.(6);Siegmund, B.(7);Rizzo, J.(8);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Mallick, M.(8);Cheng, E.(8);Armuzzi, A.(9);
Created: Friday, 11 February 2022, 3:52 PM